Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Colloid Preload Versus Colloid Coload During Cesarean Deliveries

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02393196
Recruitment Status : Unknown
Verified November 2015 by Aysun Afife Kar, Sifa University.
Recruitment status was:  Recruiting
First Posted : March 19, 2015
Last Update Posted : November 17, 2015
Sponsor:
Information provided by (Responsible Party):
Aysun Afife Kar, Sifa University

Brief Summary:
The investigators aimed to compare the methods colloid preloading and colloid coloading in terms of the incidence of maternal hypotension and impacts on neonatal outcomes. The second aim while planning the present study is to identify the method of the lowest adverse event for mother and infant and the simplest approach for the clinician.

Condition or disease Intervention/treatment Phase
Anesthesia; Adverse Effect, Spinal and Epidural Hypotension Drug: hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®) Drug: hydroxyethyl starch (%6 HES 130/0.4) (Voluven®) Phase 4

Detailed Description:
Spinal anesthesia (SA) is currently the most preferred method of anesthesia in elective cesarean deliveries. However, SA causes maternal hypotension by decreasing systemic vascular resistance over sympathetic blockade. Maternal hypotension can lead to serious adverse events both in mother and in fetus: fetal hypoxia and acidosis occur due to decreased uterine blood flow, whereas the mother may experience vertigo, nausea, vomiting, alteration in consciousness, cardiovascular collapse and arrest. Today, various strategies have been suggested for the prevention of maternal hypotension. Of these strategies, the most critical ones are fluid load before spinal anesthesia (preloading) or rapid fluid load just after spinal anesthesia (coloading) and the use of vasopressor agent. The fluids used for this purpose include crystalloids and colloids. Comparative studies performed with colloid preloading, colloid coloading and crystalloid coloading indicated that the incidence of hypotension decreased similarly with no significant difference determined between the methods of fluid loading. Researchers defended necessity of using vasopressor agent together with fluid loading methods. In daily routine; however, the investigators observe that the incidence of hypotension is lower in the patients that undergo colloid preloading as compared to the patients that undergo colloid coloading or crystalloid coloading. The investigators therefore aimed to compare the methods colloid preloading and colloid coloading in terms of the incidence of maternal hypotension and impacts on neonatal outcomes. In the present study, the investigators aimed to use 6% HES 130/0.4 (Voluven ®), which is the newer generation colloid solution. The other aim while planning the present study is to identify the method of the lowest adverse event for mother and infant and the simplest approach for the clinician.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Colloid Preload Versus Colloid Coload in Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Section Deliveries: A Prospective, Randomized, Double-Blind Comparative Study
Study Start Date : March 2015
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : March 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Group Preloading (Group P)
Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
Drug: hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)
Before spinal anesthesia
Other Name: (Voluven®; Fresenius Kabi, Bad Homburg, Germany)

Active Comparator: Group Coloading (Group C)
Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
Drug: hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)
Just after spinal anesthesia
Other Name: (Voluven®; Fresenius Kabi, Bad Homburg, Germany)




Primary Outcome Measures :
  1. Maternal hypotension. [ Time Frame: Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Maternal hypotension will be defined as at least a single administration of ephedrine within the period from induction of SA to the delivery (umbilical cord clamping). After spinal anesthesia, SAP will be measured and recorded at every minute until birth and every three minutes thereafter.

  2. Incidence of severe hypotension. [ Time Frame: Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Incidence of severe hypotension (SAP < 70% of the baseline value or SAP < 80 mmHg) will be recorded.

  3. Cumulative duration of hypotension. [ Time Frame: Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Cumulative duration of hypotension will be recorded from induction of spinal anesthesia until delivery (umbilical cord clamping).

  4. Heart rate. [ Time Frame: Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Minimum and maximum heart rate, bradycardia, atropine usage will be recorded.


Secondary Outcome Measures :
  1. Neonatal effects. [ Time Frame: Time just after delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Arterial and venous blood gas analyses will be performed from the umbilical cord after the cord clamped.

  2. Ephedrine treatment. [ Time Frame: Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    If SAB < 100 mmHg; patients will be treated by 5 mg IV bolus ephedrine, if SAB < 90 mmHg; patients will be treated by 10 mg IV bolus ephedrine.

  3. Nausea and/or vomiting. [ Time Frame: Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Incidence of nausea and/or vomiting, incidence of prepartum nausea and/or vomiting will be recorded.


Other Outcome Measures:
  1. Preoperative fasting period. [ Time Frame: Time before spinal anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    preoperative fasting period will be recorded.

  2. Preoperative hemoglobin concentration (g/dL). [ Time Frame: Time before spinal anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Before spinal anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days.

  3. Durations of anesthesia and surgery. [ Time Frame: Time between induction of spinal anesthesia until end of the anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days. ]
    Time period from induction of spinal anesthesia to skin incision (min), time period from induction of spinal anesthesia to delivery (min), time period from uterine incision to birth (sec), duration of anesthesia (min), and duration of surgery (min) will be recorded.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Singleton pregnancy
  • Gestational age ≥ 37 weeks
  • Height ≥ 150 cm and ≤ 180 cm
  • Weight > 50 kg and < 100 kg

Exclusion Criteria:

  • Gestational age > 37 weeks
  • Multiple pregnancies
  • Fetal distress
  • Preeclampsia
  • Cardiovascular disease and diabetes
  • Hematological problems
  • Local infection at intervention site
  • Abnormal coagulation tests
  • Anticoagulant use
  • Starch allergy
  • Height < 150 cm and > 180 cm
  • Weight < 50 kg and > 100 kg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02393196


Contacts
Layout table for location contacts
Contact: Aysun Afife Kar, MD +905326521313 aaysunkar@hotmail.com

Locations
Layout table for location information
Turkey
Şifa Üniversitesi, Basmane Hastanesi Recruiting
İzmir, Turkey, 35100
Sponsors and Collaborators
Sifa University
Investigators
Layout table for investigator information
Principal Investigator: Aysun Afife Kar, MD Şifa Üniversitesi, Basmane Hastanesi, İzmir, Turkey
Layout table for additonal information
Responsible Party: Aysun Afife Kar, Assistant Professor, Sifa University
ClinicalTrials.gov Identifier: NCT02393196    
Other Study ID Numbers: SifaU
First Posted: March 19, 2015    Key Record Dates
Last Update Posted: November 17, 2015
Last Verified: November 2015
Keywords provided by Aysun Afife Kar, Sifa University:
colloid preloading
colloid coloading
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypotension
Vascular Diseases
Cardiovascular Diseases
Hydroxyethyl Starch Derivatives
Plasma Substitutes
Blood Substitutes